GSK News Today (26 November 2025): Medicare Slashes Prices on Trelegy, Berenberg Lifts Target, and Buybacks Signal Confidence

GSK plc (LSE/NYSE: GSK) is in the spotlight today as U.S. Medicare unveils steep price cuts on key respiratory drugs, analysts lift their price targets, and regulators publish fresh details on the company’s ongoing share buyback programme. Here’s a complete, investor-focused look at what’s moving GSK right now.

1. Medicare’s New Drug Prices Hit GSK’s Trelegy and Breo Ellipta

The biggest GSK headline today comes from Washington: Medicare has released the second round of negotiated prices for 15 of its costliest prescription medicines, with two GSK respiratory products on the list. ^[1]

Key details:

Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) – GSK’s inhaler for asthma and COPD
- New maximum fair price (MFP): $175 per month
- 2024 list price: $654 per month
- Roughly 73% cut versus list price. ^[2]
Breo Ellipta (fluticasone furoate/vilanterol) – co‑marketed by GSK and Theravance for asthma
- New MFP: $67 per month
- Reduction of around 83% versus the 2024 list price. ^[3]

These new prices are scheduled to take effect in 2027 under Medicare’s negotiation programme created by the 2022 Inflation Reduction Act. ^[4]

Why this matters for GSK:

According to U.S. Centers for Medicare and Medicaid Services (CMS) data cited in recent coverage, Trelegy Ellipta was the second‑costliest drug in Medicare Part D in 2024, with about $5.3 billion in programme spending, behind only Novo Nordisk’s semaglutide products. ^[5]
Deep cuts to Trelegy’s reimbursed price could meaningfully lower future U.S. revenue from this flagship respiratory product, even if higher patient access partly offsets the hit to per‑unit pricing. (That’s an inference from the spending and discount figures, not something GSK has directly guided on.) ^[6]

For now, these changes are years away—they only apply from 2027—and the impact will depend on prescribing trends, competitive dynamics in respiratory care, and whether GSK shifts its commercial focus toward newer assets.

2. StreetInsider 6‑K: SEC Filing Confirms Latest Share Buybacks

U.S. investors woke up today to a fresh Form 6‑K from GSK, flagged on StreetInsider as “Form 6‑K GSK plc For: Nov 26”. ^[7]

The underlying SEC filing and related UK regulatory notices show that: ^[8]

On 24 November 2025, GSK bought back 170,000 ordinary shares (31¼ pence each) via BNP Paribas SA under its existing buyback programme.
Volume‑weighted average price (VWAP): about 1,784.93p, with trades between 1,775.50p and 1,793.50p.
After this latest purchase, GSK holds roughly 235.8 million shares in treasury, with around 4.08 billion shares in issue, meaning about 5.78% of total voting rights are held as treasury shares.

The 6‑K follows a series of “Transaction in Own Shares” notices through November covering purchases on 17, 20 and 24 November, all under the company’s £2 billion, 18‑month share buyback programme announced in February 2025. ^[9]

Taken together, these disclosures reinforce the message that GSK is actively returning capital to shareholders, which is often interpreted as a sign of management confidence in long‑term cash generation.

3. Analyst Watch: Berenberg Raises Price Target to £16.60

On the sell‑side, Berenberg is the key name in GSK news flow over the last 24 hours.

Berenberg has raised its target price on GSK shares from £16.00 to £16.60 while maintaining a “Hold” rating. ^[10]
The move follows a session with GSK CFO Julie Brown as part of the bank’s annual pharma CFO series.
Berenberg highlights Blenrep (relapsed/refractory multiple myeloma) and depemokimab (an IL‑5 targeting biologic for severe asthma) as key commercial drivers that it believes the market is underestimating, and models for FY26:
- ~5% total revenue growth
- 31% operating margin
- ~8% EPS growth ^[11]

The bank also notes that GSK trades on around 10.3x 2026 adjusted earnings, versus about 13.7x for European peers, and at a discount on its EV/NPV metrics, suggesting the stock still carries a valuation discount despite strong 2025 performance. ^[12]

4. GSK Share Price & Valuation Snapshot – 26 November 2025

On today’s numbers, GSK continues to look like a re‑rated but still income‑oriented large‑cap pharma name.

London (LSE: GSK)

According to FT market data this morning: ^[13]

Share price: ~1,795p (as of around 10:34 GMT)
Market capitalisation: ~£73.2 billion
Trailing P/E (TTM): ~13.5x
Annual dividend:64p per share, implying a yield of roughly 3.6%
Next dividend payment date:8 January 2026, with ex‑dividend date on 13 November 2025.

New York (NYSE: GSK – ADR)

MarketBeat data and live quotes show: ^[14]

ADR closing price (25 Nov 2025):$47.59
Pre‑market / extended trading today: around $47.79
Intraday spot (approx):$47.55 as of late morning UTC.

That ADR price reflects a strong 2025 run: a recent Yahoo Finance analysis noted that GSK shares have gained around 31% year‑to‑date, helped by vaccine breakthroughs, specialty medicines and a cleaner focus post‑consumer‑health spin‑off. ^[15]

5. Business Momentum: Vaccines, Oncology & Respiratory Still Driving the Story

While today’s headlines are dominated by drug‑pricing politics and capital returns, the fundamental GSK story remains anchored in specialty medicines and vaccines.

Specialty HIV & Oncology

In its Q3 2025 results, GSK raised full‑year 2025 sales and earnings forecasts after double‑digit growth in HIV and oncology, sending the shares to their highest level since mid‑2024. ^[16]

Key drivers include:

HIV portfolio (e.g., long‑acting regimens)
Jemperli (dostarlimab), where label expansions in the U.S. and EU have pushed annualised sales above $750 million, and further growth is expected as trials progress in colorectal and head & neck cancers. ^[17]

Legal risk is not absent: GSK’s oncology unit Tesaro and partner AnaptysBio are embroiled in a licensing dispute over Jemperli royalties, with litigation in Delaware Chancery Court and a trial pencilled in for July 2026. Royalties continue to flow in the meantime. ^[18]

Vaccines: RSV and Shingles

Vaccines remain a central pillar:

Arexvy (RSV vaccine) – GSK has applied to the FDA to extend the indication to high‑risk adults aged 18–49, aiming to broaden the addressable market beyond current approvals in older adults and certain at‑risk groups in their 50s. A decision is expected in the first half of 2026. ^[19]
Shingrix (shingles vaccine) – Long‑term follow‑up data show ~80% efficacy 6–11 years after vaccination in people aged 50+, highlighting the durability of protection and supporting ongoing global expansion. ^[20]
In China, regulators have recently approved Shingrix for adults 18+ at increased risk due to immunodeficiency or immunosuppression, opening up a new high‑need population in a key growth market. ^[21]

Respiratory: Beyond Trelegy & Breo

Even as Medicare’s cuts bite into Trelegy and Breo from 2027, GSK is pushing other respiratory assets, including:

Depemokimab, highlighted by Berenberg as a potentially under‑appreciated asthma driver. ^[22]
A broader respiratory portfolio showcased at ERS Congress 2025, spanning asthma, COPD and other respiratory diseases. ^[23]

The tension for investors is clear: pricing pressure on mature inhalers versus growth in newer, higher‑margin therapies.

6. Reputation & People: Marquis Who’s Who Honors GSK LIMS Leader

Not all GSK news today is about pricing and profits. In a more human‑focused update, Marquis Who’s Who has recognised Niranjana Raghunathan, a LIMS product manager at GSK since 2023, for her expertise in laboratory information management systems. ^[24]

The citation notes her role in implementing advanced LIMS platforms across multiple organisations, improving research efficiency and data integrity—a reminder that much of GSK’s pipeline strength rests on behind‑the‑scenes digital and operational capabilities, not just headline clinical trial results.

7. How Today’s Headlines Fit Together

Putting it all in one frame:

Drug pricing: U.S. Medicare’s newly negotiated prices deliver steep cuts on Trelegy and Breo, an unmistakable signal that payers are willing to be aggressive on respiratory drug costs. That’s a medium‑ to long‑term headwind for a historically important franchise. ^[25]
Capital allocation: At the same time, buybacks and dividends show GSK converting strong current cash flows into direct returns, while also narrowing share count. ^[26]
Analyst sentiment: Berenberg’s target‑price upgrade and comments about under‑recognised assets underscore the view that pipeline value in oncology and respiratory biologics may not be fully reflected in today’s valuation, even after a ~31% YTD rally. ^[27]
Fundamentals: Q3 results and guidance upgrades, Shingrix durability data, RSV expansion plans, and Jemperli growth all support the picture of a focused, post‑consumer‑health GSK that’s leaning heavily into vaccines and specialty medicines. ^[28]

For shareholders and watchers, 26 November 2025 is a day where macro policy, sell‑side views and corporate finance are all converging on the GSK story.

Quick Summary for Readers & Potential Investors

If you follow drug pricing: GSK is one of the clearest case studies in how U.S. Medicare negotiations can reshape the economics of mature blockbusters.
If you follow earnings & valuation: Analyst target upgrades, rising earnings forecasts, and sustained buybacks point to a management team leaning into a multi‑year growth plan, despite policy headwinds.
If you follow the science: The real long‑term story still lives in RSV, shingles, HIV and oncology, where GSK aims to offset pricing pressure with innovation‑led growth.

Note: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Always do your own research or consult a qualified financial adviser.